Post-earnings recap
Reported
Fri, Aug 5, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising by 2.86%. However, the lack of revenue data and management commentary leaves uncertainties about the company's future performance. Investors may want to monitor upcoming reports for more insights.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +33.33% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.